login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
LIPOCINE INC (LPCN) Stock News
USA
-
Nasdaq
- NASDAQ:LPCN -
US53630X2036
-
Common Stock
3.1
USD
+0.01 (+0.32%)
Last: 12/4/2025, 8:00:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
LPCN Latest News, Press Relases and Analysis
All
Press Releases
a month ago - By: Lipocine Inc.
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025
3 months ago - By: Lipocine Inc.
Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference
3 months ago - By: Lipocine Inc.
Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025
6 months ago - By: Lipocine Inc.
Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada
7 months ago - By: Lipocine Inc.
Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology
7 months ago - By: Benzinga
- Mentions:
PTIX
BCLI
HCTI
FBRX
...
12 Health Care Stocks Moving In Monday's Pre-Market Session
10 months ago - By: Lipocine Inc.
Lipocine Receives Updated Regulatory Guidance on LPCN 1154
a year ago - By: BusinessInsider
LPCN Stock Earnings: Lipocine Beats EPS, Misses Revenue for Q2 2024
2 years ago - By: InvestorPlace
LPCN Stock Earnings: Lipocine Beats EPS for Q1 2024
7 months ago - By: Lipocine Inc.
Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase
7 months ago - By: Benzinga
- Mentions:
AGEN
RGC
OMER
WORX
...
12 Health Care Stocks Moving In Monday's Intraday Session
7 months ago - By: Lipocine Inc.
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025
a year ago - By: Lipocine Inc.
Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session
a year ago - By: Lipocine Inc.
Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024
2 years ago - By: BusinessInsider
LPCN Stock Earnings: Lipocine Beats EPS for Q4 2023
2 years ago - By: InvestorPlace
LPCN Stock Earnings: Lipocine Beats EPS for Q4 2023
2 years ago - By: Lipocine Inc.
Lipocine to Present at 36th Annual Roth Conference
a year ago - By: Lipocine Inc.
Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®
a year ago - By: Lipocine Inc.
Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference
a year ago - By: InvestorPlace
LPCN Stock Earnings: Lipocine Beats EPS, Misses Revenue for Q2 2024
a year ago - By: Lipocine Inc.
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study
1 years ago - By: Lipocine Inc.
Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024
2 years ago - By: Lipocine Inc.
Lipocine to Present at Biotech Showcase 2024
2 years ago - By: InvestorPlace
- Mentions:
FGEN
NVCT
RLMD
ANIX
...
7 Penny Biotech Stocks to Triple Your Investment
2 years ago - By: Lipocine Inc.
Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024
2 years ago - By: Lipocine Inc.
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
2 years ago - By: Lipocine Inc.
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
2 years ago - By: Lipocine Inc.
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
2 years ago - By: Lipocine Inc.
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
2 years ago - By: Lipocine Inc.
Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals
2 years ago - By: InvestorPlace
- Mentions:
ELAB
KPRX
FBLG
GMM
...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
2 years ago - By: Seeking Alpha
- Mentions:
HALO
Lipocine licenses Tlando testosterone therapy to Verity Pharma (NASDAQ:LPCN)
2 years ago - By: Lipocine Inc.
Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada
2 years ago - By: Seeking Alpha
Lipocine files for $150M mixed shelf (NASDAQ:LPCN)
2 years ago - By: Lipocine Inc.
Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023
Please enable JavaScript to continue using this application.